Chemotherapy News and Research

Latest Chemotherapy News and Research

TGen presents two key studies at 14th World Conference on Lung Cancer

The Translational Genomics Research Institute (TGen) is presenting two key studies, including one today, at the 14th World Conference on Lung Cancer, July 3-7 in Amsterdam.

7 Jul 2011

Hydrogel capsule could simultaneously deliver different types of drugs

Researchers at the Georgia Institute of Technology have designed a multiple-compartment gel capsule that could be used to simultaneously deliver drugs of different types. The researchers used a simple "one-pot" method to prepare the hydrogel capsules, which measure less than one micron.

7 Jul 2011

Smoking, social class may lead to POF in women

POF is not only associated with infertility but also with significantly increased morbidity and mortality, as well as a decreased quality of life equivalent to that of people with type 2 diabetes or rheumatoid arthritis, said Dr. Rumana Islam, from Imperial College, London, UK.

6 Jul 2011

New CRM simulation model for Canadian Partnership Against Cancer

If Canada's smoking rates were cut by half to an average national rate of 11% within five years, it would result in 35,900 fewer cases of lung cancer by 2030 and save $656 million in treatment costs, according to analysis using a new web-enabled platform developed for the Canadian Partnership Against Cancer and presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

6 Jul 2011

Review of non-smoker patient with lung cancer to be presented at IASLC conference

A first-of-its-kind study of a patient with lung cancer who never smoked will be presented today by TGen and the Virginia G. Piper Cancer Center at Scottsdale Healthcare at the 14th World Conference on Lung Cancer, July 3-7 in Amsterdam.

6 Jul 2011

Patients with high EGFR expression more likely to benefit from cetuximab plus chemotherapy

High epidermal growth factor receptor expression was a good predictor of which lung cancer patients would survive longer when cetuximab was added to first-line chemotherapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

5 Jul 2011

Erlotinib phase III study results on lung cancer presented at IASLC conference

In the first phase III study to include Western lung cancer patients, first-line treatment with erlotinib (Tarceva) nearly doubled progression-free survival compared with chemotherapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

5 Jul 2011

MGH researchers discover new plant compounds that block blood vessel growth

Massachusetts General Hospital (MGH) researchers have discovered the first of an entirely new class of antiangiogenesis drugs - agents that interfere with the development of blood vessels.

2 Jul 2011

Medicare to cover 2 expensive cancer drugs

Medicare confirmed on Thursday that it would continue to pay for two expensive cancer drugs that had been at the center of debate — Avastin from Genentech for breast cancer and Provenge from Dendreon for prostate cancer.

2 Jul 2011

The Max Cure Foundation, SWCRF partner to fund pediatric cancer research

The Max Cure Foundation and the Samuel Waxman Cancer Research Foundation have partnered to establish a fund in pediatric cancer research. With that goal in mind, the two Foundations are proud to announce the award of $100,000 to Erwin G. Van Meir, Ph.D., of Emory University School of Medicine in Atlanta.

1 Jul 2011

Ovarian cancer molecular updates

In a new study a genetic mutation was found in the most common form of ovarian cancer. This according to the US scientists could pave the way for a more effective treatment of the disease. The detailed genetic map already helped scientists identify existing drugs with the potential for treating the mutations found in ovarian cancer tumors and also identified mutations that could respond to new drugs.

1 Jul 2011

Avastin for breast cancer still covered by Medicare despite FDA indecision

The Medicare will continue to cover Avastin for breast cancer treatment even if U.S. Food and Drug Administration Commissioner Peggy Hamburg decides to withdraw Avastin for such use, according to Don McLeod, a spokesman for the Centers for Medicare and Medicaid. McLeod said, in his statement, “The FDA decision, when it comes, does not affect CMS.”

1 Jul 2011

Positive results from Nexavar Phase 2b trial on breast cancer presented at ASCO

Accelerated Community Oncology Research Network, Inc., reported positive results of a large double-blind, randomized Phase 2b trial in patients with breast cancer at the American Society of Clinical Oncology (ASCO) 47th annual meeting in Chicago, June 3-7.

1 Jul 2011

Molecular radiotherapy offers hope for children with neuroblastoma

A new treatment option may soon be available for children with neuroblastoma according to research published in the July issue of The Journal of Nuclear Medicine.

30 Jun 2011

New technology reduces stress of scheduling chemotherapy treatments

The stress of scheduling chemotherapy treatments has been substantially reduced by a new technology created and implemented by a team of researchers from the Sauder School of Business at the University of British Columbia and the BC Cancer Agency.

30 Jun 2011

Sensitivity of bladder cancer cells linked to chemotherapy and expression of miR-34a gene

Researchers at the UC Davis Cancer Center have discovered a way of sensitizing muscle-invasive bladder cancer cells so that they succumb to the toxic effects of chemotherapy. The finding adds to mounting evidence that tiny strands of RNA - called microRNA - play key roles in some of the deadliest types of cancer.

30 Jun 2011

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Genentech, a member of the Roche Group, announced today that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin in combination with paclitaxel chemotherapy for previously untreated HER2-negative metastatic breast cancer.

30 Jun 2011

FDA looks at Avastin risks

The US Food and Drug Administration is holding a two-day hearing that pits the FDA's Center for Drug Evaluation and Research against Genentech, that manufactures breast cancer drug Avastin. A handful of breast cancer patients testified Tuesday that Avastin helped in treating their metastatic breast cancer but a review of studies conducted by the FDA's Center for Drug Evaluation and Research suggests the risks outweigh the benefits of Avastin for treating breast cancer, FDA officials said at the hearing.

29 Jun 2011

A.P. Pharma enters into definitive agreements for $24M private placement of common stock and warrants

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that it has entered into definitive agreements with certain new and existing accredited investors providing for a private placement of common stock and warrants in which the Company will receive $24 million in gross proceeds.

29 Jun 2011

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

Signal Genetics, a privately held predictive genetic testing company focusing on oncology, and DiagnoCure, Inc., a life sciences company that develops and commercializes high-value cancer diagnostic tests, today announced a collaboration arrangement valued at US$13.3M over the first five years.

29 Jun 2011